To evaluate the efficacy and safety of sodium cantharidate combined with chemotherapy in the treatment of advanced gastric cancer. Methods:MEDLINE, Pubmed, Cochrane library retrieval, Chinese biomedical literature database (CBM), Chinese Journal Full-text Database (CNKI), VIP Chinese PSTP (VIP) and Wanfang database (WanFang) were searched from their inception to September 2016 by computer, and the randomized controlled trails(RCTs) about sodium cantharidinate combined with chemotherapy for advanced gastric cancer were included. The methodological quality of the included studies were evaluated according to the criteria of Cochrane Handbook for Systematic Reviews of interventions, then the relevant data extracted, and RevMan5.3 software was used for data analysis. Results:Seven studies involving 450 participants were included, among which 231 participants took part in sodium cantharidate plus chemotherapy and 219 chemotherapy. The results of meta-analysis showed that sodium cantharidinate could improve the quality of life［RR=2.14，95%CI(1.55，2.96), P<0.00001］, and decrease bone marrow suppression［RR=0.69，95%CI(0.59，0.81), P<0.00001］ and gastrointestinal side-effects［RR=0.61，95%CI(0.52，0.72), P<0.00001］.But had little advantage in improving patients' recent effective rate.Conclusion:Recent studies suggest that treating the advanced grastric cancer with sodium cantharidinate could improve the quality of life, decrease bone marrow suppression and gastrointestinal side-effects. More hige quality and large sample studies are needed in the future to provide more reliable evidence for evidence-based medicine(EBM).